Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

chronic inflammatory demyelinating polyradiculoneuropathy News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

New research identifies data-driven subtypes of chronic inflammatory demyelinating polyneuropathy (CIDP), challenging existing classification systems. This study highlights the clinical heterogeneity of CIDP, which may impact future diagnostic and treatment approaches.

A recent study discusses the use of matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy (CIDP). The authors emphasize the need for improved methodologies to interpret current evidence and enhance future studies in this area.

A recent study identifies newly developing IgM anti-GD1a/GD1b ganglioside monoclonal gammopathy in a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This discovery may provide insights into the pathophysiology of CIDP and potential therapeutic targets.

A recent study evaluates the efficacy and tolerance of a combination of targeted therapies for asthma and chronic inflammatory rheumatism. The findings contribute to understanding treatment options for these conditions.

Recent research highlights the current status and future directions in the clinical practice of chronic inflammatory demyelinating polyneuropathy (CIDP). This review discusses advancements in understanding the disease and potential therapeutic approaches.

Sanofi has discontinued its Phase 3 study for a complement inhibitor drug targeting chronic inflammatory demyelinating polyneuropathy due to underwhelming efficacy results. This decision reflects broader challenges within the drug class, impacting future development prospects.

A corrigendum has been published regarding the diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20. This update addresses previous findings in the Journal of the Neurological Sciences.

A recent study published in PubMed examines the quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The findings highlight the significant impact of this rare disease on daily living and overall well-being.

The CMP-MYTHiC study investigates the use of colchicine in patients with chronic inflammatory cardiomyopathy. This research aims to provide insights into the therapeutic potential of colchicine for this rare condition.

A case report details an 89-year-old man with chronic inflammatory demyelinating polyradiculoneuropathy who developed encephalitis caused by human herpesvirus 6 variant A while on prednisolone. This highlights potential complications in elderly patients with underlying neurological conditions.

A personal story highlights how a diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) motivated the author to engage in advocacy efforts. The narrative emphasizes the importance of community support and awareness for rare diseases.

Not rare diseases news,news about your rare disease.